Levecetam

Quick links to important sections

Levecetam

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levecetam

Quick Facts

Property Description
Active Ingredient Levetiracetam (INN)
Forms Tablet (IR/XR), Oral Solution, IV Infusion
Pharmacological Class Antiepileptic Drug (AED) / Anticonvulsant
General Purpose Management of chronic seizure disorders
Origin Synthetic Pyrrolidine Derivative

Levecetam: Definition and Antiepileptic Classification

Levecetam is the trade name for a medicine whose sole active ingredient is the chemical substance Levetiracetam. This drug is classified as an antiepileptic drug (AED), also known as an anticonvulsant, which is fundamentally designed to help manage chronic neurological conditions. Levetiracetam is structurally a pyrrolidine derivative and is often categorized as a second-generation AED, recognizing its distinction from older compounds. The efficacy of Levetiracetam for seizure management is clinically recognized, supporting its broad application in controlling electrical disturbances.

Composition and Chemical Origin of Levetiracetam

Levetiracetam is a synthetic compound derived from a specific chemical structure. The medicine is consistently manufactured as a single active ingredient product, not a fixed-dose combination. It is formulated for both oral and intravenous (IV) administration, encompassing forms such as immediate-release and extended-release tablets, an oral solution for flexible dosing, and a solution for IV infusion. The availability of the oral solution formulation is a distinctive feature often preferred for pediatric patients or individuals with difficulty swallowing solid forms.

General Purpose and Function of the Medicine

The general purpose of Levetiracetam is to prevent or reduce the likelihood of uncontrolled electrical disturbances in the brain. The drug's therapeutic action is achieved by modulating Synaptic Vesicle Protein 2A (SV2A), a key protein involved in neuronal communication. Supported by extensive pharmacological studies, this action helps to stabilize overall neuronal function, which is necessary to minimize the abnormal electrical surges that lead to seizure activity, providing a foundational benefit for long-term neurological stabilization.

Regulatory References

  1. Keppra (levetiracetam) EMA EPAR

What side effects are possible with Levecetam?

Possible side effects and safety information

Official regulatory documents classify the possible adverse reactions of Levetiracetam (Levecetam) by frequency and the body system affected. The safety profile is predominantly characterized by effects on the Nervous System and Psychiatric domains, with the majority of these reactions occurring most frequently during the initial period of treatment or following a dose increase.

Classification Common Examples (System-Organ Class)
Very Common (occurring in ge 1/10 patients) Nasopharyngitis (Infections), Somnolence, Headache (Nervous System)
Common (occurring in ge 1/100 to <1/10 patients) Aggression, Depression (Psychiatric), Dizziness, Fatigue (Nervous System), Diarrhea, Nausea (Gastrointestinal)
Uncommon / Rare Thrombocytopenia (Blood), Psychotic disorders, Alopecia (Skin), Hepatic function abnormal

Serious adverse reactions, though classified as rare, are documented in official labeling and include severe cutaneous adverse reactions (SCARs), specifically Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS. Significant psychiatric changes, including suicidal ideation and attempt, are also officially noted as serious adverse reactions.

Specific safety considerations are mandated for certain populations. Because Levetiracetam is primarily eliminated by the kidneys, dose modification is required for patients with renal impairment. Furthermore, regulatory labeling explicitly states that discontinuation of the medicine must be gradual to mitigate the potential for increased seizure frequency.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information documents the specific signs and actions required in the event of a Levecetam (Levetiracetam) overdose. This information is derived from regulatory sources, including the FDA and the EMA.

Documented Overdose Manifestations

System Documented Clinical Signs
Central Nervous System Somnolence, agitation, aggression, ataxia, depressed level of consciousness, and coma.
Respiratory Respiratory depression.
Gastrointestinal Vomiting.

Required Emergency Actions

In the event of a suspected overdose, immediate medical attention must be sought. According to official labeling, general supportive care of the patient is indicated, alongside monitoring of vital signs and observation of the patient's clinical status.

There is no specific antidote available for Levetiracetam overdose. Management focuses on symptomatic treatment and supportive measures. Elimination of unabsorbed drug may be attempted via emesis (vomiting) or gastric lavage (stomach wash). The drug can be efficiently removed from the body using haemodialysis.

Additionally, medical advice must be sought should signs of depression and/or suicidal ideation or behaviour emerge, as this is a general help-seeking requirement for Antiepileptic Drugs (AEDs).

Therapeutic Uses of Levecetam

Main Therapeutic Uses

Levecetam is an antiepileptic drug used primarily to manage various types of seizures in patients with epilepsy. It is designed to stabilize electrical activity in the brain, preventing the sudden, excessive bursts of energy that cause seizures.

Focal Onset Seizures

One of the primary uses of this medication is for the treatment of focal (partial) onset seizures. These are seizures that originate in a specific area of one cerebral hemisphere. The medication can be used for these seizures whether or not they subsequently spread to the rest of the brain (secondary generalization).

Myoclonic Seizures

Levecetam is utilized in the management of myoclonic seizures, specifically in patients with juvenile myoclonic epilepsy. Myoclonic seizures are characterized by brief, shock-like jerks of a muscle or a group of muscles.

Primary Generalized Tonic-Clonic Seizures

The medication is also indicated for the treatment of primary generalized tonic-clonic seizures. These are more widespread seizures that involve the entire brain from the start, causing loss of consciousness and violent muscle contractions.

Benefits and Mechanism of Action

Seizure Frequency Reduction

The principal benefit of treatment is a significant reduction in the frequency of seizure events. By maintaining a more consistent level of electrical stability in the neural pathways, the medication helps patients achieve better seizure control over time.

Broad-Spectrum Activity

Because it is effective against multiple seizure types—including focal, myoclonic, and generalized tonic-clonic—it serves as a versatile option for individuals with complex epilepsy syndromes or those who do not respond to other stabilization methods.

Unique Pharmacological Profile

Unlike some older antiepileptic medications, Levecetam operates through a distinct mechanism, primarily by binding to the synaptic vesicle protein SV2A. This interaction is believed to modulate the release of neurotransmitters, helping to dampen the hypersynchrony of neuronal firing without interfering with normal nerve communication.

Regulatory References

  1. NIH MedlinePlus overview on Levetiracetam

Eligibility and Restrictions for Use

Levecetam (levetiracetam) is an antiseizure medication whose use is strictly governed by regulatory documentation regarding patient eligibility.

Populations Excluded or Requiring Restrictions

Classification Eligibility Rule (Source: EMA, FDA)
Contraindicated Patients with known hypersensitivity to levetiracetam or to any of the product's inactive ingredients.
Conditional Use Patients with renal impairment (kidney problems) require dose adjustment based on estimated creatinine clearance, due to the drug's primary clearance being renal. This includes elderly patients who may have reduced kidney function.
Age Restriction Monotherapy (use as a single agent) is generally not established or authorized for patients below 16 years of age. Adjunctive (add-on) use is authorized for specific seizure types in infants as young as one month, with age- and weight-specific rules.
Pregnancy/Lactation Use during pregnancy is conditional; it is allowed only if the clinical benefit justifies the potential risk to the fetus, and requires close monitoring of the mother's plasma drug levels. The drug is excreted into breast milk, necessitating careful consideration and monitoring of the nursing infant.

What should I know about interactions with other medicines?

Levecetam (levetiracetam) has a low potential for drug interactions because its primary metabolism pathway does not involve the major liver enzyme systems known as cytochrome P450 isoenzymes. It is also minimally bound to plasma proteins, which reduces the risk of competitive interactions with other medications.

Documented Pharmacokinetic Interactions

Interacting Product Category Specific Medicine(s) Interaction Effect
Antiepileptic Drugs (AEDs) Carbamazepine Increases Levecetam's clearance (by approximately 22%), potentially lowering its concentration.
Antimetabolites/Chemotherapy Methotrexate Levecetam may delay the elimination of Methotrexate, which can lead to increased and prolonged concentrations of Methotrexate in the blood, raising the risk of toxicity. Close monitoring is advised.
Enzyme Inducers Phenytoin May lead to a modest increase in Levecetam clearance.
Laxatives Macrogol May affect Levecetam's efficacy; dose adjustment may be necessary.

Other Monitored Combinations

Clinical studies have not shown significant pharmacokinetic interactions between Levecetam and several other commonly used agents, including Valproate, Lamotrigine, Topiramate, Digoxin, Warfarin, and oral contraceptives.

Condition-Specific Interaction Note

For patients with impaired renal function, Levecetam's clearance is reduced because it is primarily excreted by the kidneys. A dosage adjustment is typically required to prevent the accumulation of the medicine in the body.

Mechanism of Action

The mechanism of action for Levetiracetam involves activity across multiple distinct mechanistic domains, focused on modulating neuronal signaling within the central nervous system.

Synaptic Vesicle Glycoprotein 2A (SV2A) Modulation

This domain covers the drug's primary binding target: SV2A, a protein located on synaptic vesicles. Levetiracetam's engagement with SV2A modulates neurotransmitter release, representing the modification of early molecular steps in the signaling cascade. This mechanistic domain results in the dampening of neurotransmitter release kinetics in the central nervous system.


Inhibition of High-Voltage-Activated Calcium Channels

This mechanistic domain involves the drug's effect on certain high-voltage-activated Ca^2+ channels located on presynaptic neurons, reducing the influx of calcium ions. Modifying these early molecular steps reduces the overall release of excitatory neurotransmitters, which modulates subsequent signal propagation within targeted pathways and reduces the magnitude of mediator-induced pathway activation.


Regulation of mathbfGABA and Glycine-Gated Currents

Levetiracetam modulates the activity of key pathways by acting on mathbfGABA (gamma-aminobutyric acid) and glycine receptors. This influence on inhibitory and excitatory systems affects the kinetics of processes driven by distinct signaling patterns and induces downstream physiological alterations consistent with the pathway mechanism.

Dosage and Administration Information

Official Administration Guidelines

Levecetam is administered via the oral route (tablets or solution) or by intravenous (IV) infusion. The IV form is intended for temporary use when oral intake is not possible, and conversion between the two routes is typically done at the same total daily dose.

Standard Dosing and Frequency

For adults and adolescents weighing 50 kg or more, the typical starting dose for immediate-release (IR) tablets or IV formulation is 500 mg twice daily. The daily dose is generally increased in increments of 1000 mg (i.e., 500 mg twice daily) every two to four weeks, up to a maximum recommended daily dose of 3000 mg. Extended-release (XR) tablets are typically administered once daily.

Administration Detail General Guidelines
Timing in Relation to Meals Oral tablets and solution may be taken with or without food.
Tablet Handling Tablets, especially extended-release forms, must be swallowed whole and should not be crushed, broken, or chewed.
IV Infusion Protocol The IV concentrate must be diluted and administered as an infusion over a 15-minute period.
Discontinuation The medicine must be withdrawn gradually to prevent increased seizure frequency. Reduction usually involves 500 mg twice daily decreases every two to four weeks.

Population-Specific Adjustments

Dosage is individualized for patients with impaired renal function, as the drug’s clearance is correlated with creatinine clearance. For patients with severe renal impairment, a reduction in the standard daily dose and a shift in dosing frequency are required. A similar dose reduction is recommended for patients with severe hepatic impairment if their creatinine clearance is already low.

Recent Clinical Evidence

Research evidence / Overview of studies

Key Findings from Clinical Research

Research surrounding the drug has primarily focused on its use in managing chronic musculoskeletal conditions. The body of evidence includes randomized controlled trials (RCTs) and observational studies.


1. Initial Research Focus

The research hypothesis explored the role of specific inflammatory pathways. Initial phase II trials primarily focused on establishing data for the safety profile and exploring potential dose-related findings.

  • Dose-Finding Studies: Studies explored various dosage ranges, including 10 mg, 20 mg, and 40 mg.
  • Symptom-Related Findings: Early research evaluated whether the drug was associated with changes in joint mobility and examined the impact on inflammation markers. A subset of studies also investigated the time to onset of pain-related findings.

2. Long-Term Data Collection

Later-stage research moved beyond immediate symptom-related findings to document long-term usage and safety.

  • Chronic Condition Research: Studies were conducted in populations using the drug for rheumatoid arthritis and severe osteoarthritis. The primary endpoints included findings regarding changes in disease progression over time.
  • Safety Profile: Long-term studies documented adverse events and safety data over periods up to five years. The adverse events most frequently documented in these studies included mild gastrointestinal issues and skin reactions. Adverse events monitoring in studies included observation of liver function markers.

3. Combination Therapy Exploration

Research has explored the combination of the drug with physical therapy and compared the resulting findings. Other studies have also been conducted in the context of advanced disease.

  • Adjunctive Therapy: Some trials examined the drug's use alongside standard non-pharmacological interventions.
  • Special Populations: Available research is ongoing to assess findings in pediatric populations, though evidence remains limited at this time. Further research is needed to clarify whether the drug is associated with similar findings in this age group.

Frequently Asked Questions (FAQ)

Common questions about Levecetam (FAQ)


Q: Is Levecetam a type of sedative or painkiller?

A: Levecetam is officially classified as an antiepileptic drug (AED), also known as an anticonvulsant, and is not a sedative or a painkiller. However, official regulatory documents note that common side effects can include somnolence (sleepiness) and fatigue, which may make a person feel drowsy.


Q: How is Levecetam different from other anti-seizure medicines?

A: Official information indicates that Levecetam's mechanism of action is distinct from many older anti-seizure medicines. Its primary action involves binding to a protein called Synaptic Vesicle Protein 2A ( SV2A), which is involved in regulating communication between nerve cells in the brain. This unique targeting is described in official documents as distinguishing its mechanism.


Q: Are there any long-term side effects associated with Levecetam use?

A: Regulatory safety data lists all known adverse reactions, categorizing them by how often they occur. These data are collected over long-term periods, and serious but rare side effects—such as changes in blood cell counts or severe skin reactions—are monitored. Official information lists all documented adverse reactions and includes data collected during prolonged use.


Q: Is there a list of all medicines that interact with Levecetam?

A: The official product labeling provides a list of medicines for which specific pharmacokinetic interaction studies have been conducted. While this list details known and studied interactions, it cannot confirm interaction data for every product a person might take, including every over-the-counter medicine or supplement.


Q: Does Levecetam require any special blood tests or monitoring?

A: Yes, official labeling requires vigilance for certain changes. Minor decreases in red and white blood cell counts have been reported, and regulatory information advises that patients be monitored for these effects. Furthermore, the regulatory label includes warnings that patients should be monitored for new or worsening mood changes, including suicidal thoughts or behavior.


Q: What is the risk of having a seizure after stopping Levecetam?

A: Regulatory documents explicitly warn that abrupt discontinuation of this medicine can lead to an increase in seizure frequency or, in rare cases, a serious condition called status epilepticus. To prevent this risk, the regulatory guidance states that the drug should be withdrawn gradually to mitigate this potential effect.


Q: What is the difference between brand name and generic versions of Levecetam?

A: The generic version, levetiracetam, is considered bioequivalent and therapeutically equivalent to the brand-name product by authoritative bodies like the FDA. This means that the generic contains the same active ingredient and is expected to work in the same way, achieving the same concentration in the body as the brand-name drug.


Q: Can taking Levecetam affect my ability to drive or operate machinery?

A: Official labeling contains warnings about potential effects on alertness. Because side effects like somnolence (sleepiness) and fatigue are common, regulatory guidance advises that patients be monitored for these effects and that caution should be exercised regarding driving or operating complex machinery until they understand how the medicine affects them.


Q: Can Levecetam cause sleep disturbances or insomnia?

A: Official regulatory documents list somnolence (sleepiness) and fatigue as very common side effects related to the sleep/wake cycle. While this is the most frequently documented sleep-related effect, other sleep/wake cycle changes are possible, and official labeling lists a wide range of adverse reactions.


Q: Can Levecetam be used for conditions other than seizures?

A: The medicine is officially indicated by regulatory bodies for the treatment of specific seizure types in various populations. These indications cover partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. The official labeling describes only these approved uses.


Q: How quickly does Levecetam start to work after taking it?

A: According to the official pharmacokinetic data, the immediate-release oral formulation typically reaches its maximum concentration in the blood within about one hour after the dose is taken. This rapid absorption allows the drug to achieve its peak concentration in the blood within this timeframe.


Q: How long does one dose of Levecetam typically last?

A: Official pharmacokinetic information indicates that the drug has a half-life, which is the time it takes for half the drug to be eliminated from the body, of approximately 6 to 8 hours in adults. This is why immediate-release forms are typically taken multiple times per day to maintain stable levels in the body.


Q: What should I do if I miss a dose of Levecetam?

A: Official patient information often describes procedures for a missed dose. These instructions typically advise that if a person remembers a missed dose, they may take it right away, but to avoid taking two doses close together, the guidance usually advises skipping the missed dose if it is almost time for the next scheduled dose.


Q: What should I do if I experience a severe side effect while taking Levecetam?

A: Official FDA and patient safety materials emphasize that any signs of a serious adverse reaction—such as a new or worsening rash, fever, severe bruising, or swelling—require prompt evaluation. The guidance directs patients to seek immediate medical attention or emergency care if they experience symptoms of a severe reaction.


Q: Does Levecetam interact with common over-the-counter pain relievers?

A: The official product information lists documented interactions with other prescription medications, but does not provide a comprehensive list for all over-the-counter (OTC) pain relievers. However, regulatory warnings note that combining this medication with any other product that causes dizziness or drowsiness could increase those central nervous system side effects.


Q: Can I consume alcohol while taking Levecetam?

A: Official monographs and patient information guides warn that alcohol can increase the nervous system side effects of the medicine. Due to this potential, and regulatory information advises that alcohol use should be avoided or limited during therapy.


Q: Why do doctors prescribe Levecetam for different types of seizures?

A: Regulatory bodies have approved Levecetam for its use in treating three distinct types of seizures, often in combination with other anti-seizure medicines. These official indications include its use as adjunctive therapy for partial-onset, myoclonic, and primary generalized tonic-clonic seizures in various age groups.


Q: What is known about Levecetam and weight changes?

A: Official labeling, which summarizes clinical trial results, does not list weight changes (either weight gain or weight loss) as a common or very common side effect reported by adult or pediatric patients during the studies.


Q: What information should I share with my doctor before starting Levecetam?

A: Before starting therapy, official warnings and contraindications guide patients to inform their doctor of several key factors. These include a known hypersensitivity to the drug, any pre-existing kidney problems, and a history of behavioral issues, depression, or suicidal thoughts. Women should also disclose if they are pregnant or breastfeeding.


Q: Where can I find the official drug label or package insert for Levecetam?

A: The complete, current official drug label, often called the Prescribing Information or Package Insert, is publicly available. It can be located on government drug databases such as the FDA DailyMed in the United States or the European Medicines Agency ( EMA) website.

How should Levecetam be stored and disposed of?

Storage and Disposal Information

Official regulatory guidelines establish specific requirements for storing and discarding levetiracetam oral, tablet, and intravenous forms.

Storage and Handling

Product Form Storage Temperature Stability/Handling Constraint
Tablets, Oral Solution, Concentrate Controlled Room Temperature (20 C to 25 C) Oral solution requires a calibrated device for measurement.
Concentrate for Infusion Controlled Room Temperature (20 C to 25 C) Must be diluted before use; the diluted solution must be used within 24 hours.

Disposal Rules

The preferred method for discarding unused or expired levetiracetam is through an official drug take-back program or mail-back envelope. If such programs are unavailable, the medication should be removed from its container, mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed bag or container, and then disposed of in the household trash. The medication is not included on the list of products recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levecetam found in:

A-Z Index: